RBC Cuts PTC Therapeutics (PTCT) Price Target by Nearly 20%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Jefferies Cuts PTC Therapeutics (PTCT) Target to $8
March 1, 2016 9:13 AM ESTJefferies analyst, Gena Wang, cut her PT on TC Therapeutics (NASDAQ: PTCT) after hearing more color on the RTF letter and German pricing status on the 4Q15 earnings call. Consistent with her thesis, the FDA questioned ataluren effectiveness in DMD leaving... More
Wedbush Downgrades PTC Therapeutics (PTCT) to Neutral
March 1, 2016 7:29 AM ESTWedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower Translarna estimates shift risk/reward.
Analyst Heather Behanna commented, "Though we still believe Translarna has a good chance of full EU approval, we are... More
Cowen Downgrades PTC Therapeutics (PTCT) to Market Perform
March 1, 2016 7:27 AM ESTCowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
... MorePTC Therapeutics (PTCT) Misses Q4 EPS by 25c
February 29, 2016 4:02 PM ESTPTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($1.50), $0.25 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $13.2 million.
The company also offered the following updates:
Refuse to File letter received from the FDA regarding Translarna for nonsense mutation Duchenne muscular dystrophy (nmDMD). The letter from the U.S. Food and Drug Administration (FDA)... More